These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36759424)

  • 41. In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products.
    Tsuji G; Kurohara T; Shoda T; Yokoo H; Ito T; Masada S; Uchiyama N; Yamamoto E; Demizu Y
    Chem Pharm Bull (Tokyo); 2024; 72(2):166-172. PubMed ID: 38296559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PERIOCULAR HIGH RISK BCCS AFTER ADDITIONAL/PARALLEL INTAKE OF TORASEMIDE, MOXONIDINE AND MIRABEGRON: IMPORTANT LINKS TO SKIN CANCER RELATED (PHOTO-) NITROSOGENESIS IN THE CONTEXT OF PHARMACO-ONCOGENESIS.
    Tchernev G; Dimova D
    Georgian Med News; 2024 Feb; (347):70-76. PubMed ID: 38609117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parts per billion of nitrite in microcrystalline cellulose by ion chromatography mass spectrometry with isotope labeled internal standard.
    Zhu K; Kerry M; Serr B; Mintert M
    J Pharm Biomed Anal; 2023 Oct; 235():115648. PubMed ID: 37611458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.
    Shakleya D; Asmelash B; Alayoubi A; Abrigo N; Mohammad A; Wang J; Zhang J; Yang J; Marzan TA; Li D; Shaklah M; Alsharif FM; Desai S; Faustino PJ; Ashraf M; O'Connor T; Vera M; Raw A; Sayeed VA; Keire D
    J Pharm Sci; 2023 Dec; 112(12):3075-3087. PubMed ID: 37364772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The EU Response to the Presence of Nitrosamine Impurities in Medicines.
    Ruepp R; Frötschl R; Bream R; Filancia M; Girard T; Spinei A; Weise M; Whomsley R
    Front Med (Lausanne); 2021; 8():782536. PubMed ID: 34869504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: Effects of metformin and hypromellose used in drug product formulation.
    Hao G; Hu R; Wang X; Gao P; Wang L; Jiang M; Xin L; Tan G; Zhao Y; Sun F; Chu D; Lv J; You J; Huang F; Song X
    J Pharm Biomed Anal; 2023 Jan; 222():115066. PubMed ID: 36191442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Overview and Discussion of N-nitrosamine Considerations for Orally Inhaled Drug Products and Relevance to Other Dosage Forms.
    Khan HS; Despres-Gnis F; Stults CLM; Mullis J; Nugara N; Sen A; Nagao L
    AAPS PharmSciTech; 2023 Jan; 24(1):37. PubMed ID: 36653673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies.
    Felter SP; Ponting DJ; Mudd AM; Thomas R; Oliveira AAF
    Regul Toxicol Pharmacol; 2023 Sep; 143():105459. PubMed ID: 37474097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis.
    Hecht SS
    Proc Soc Exp Biol Med; 1997 Nov; 216(2):181-91. PubMed ID: 9349687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient In-Use Stability Testing of FDA-Approved Metformin Combination Products for N-Nitrosamine Impurity.
    Dharani S; Mohamed EM; Rahman Z; Khan MA
    AAPS PharmSciTech; 2024 Jan; 25(1):19. PubMed ID: 38267707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Volatile N-nitrosamines in meat products: Potential precursors, influence of processing, and mitigation strategies.
    De Mey E; De Maere H; Paelinck H; Fraeye I
    Crit Rev Food Sci Nutr; 2017 Sep; 57(13):2909-2923. PubMed ID: 26528731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nitrosamine Impurities in Angiotensin Receptor Blockers.
    Shephard EA; Nawarskas JJ
    Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
    Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
    J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
    Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
    Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damage.
    Fine J; Allain L; Schlingemann J; Ponting DJ; Thomas R; Johnson GE
    Regul Toxicol Pharmacol; 2023 Dec; 145():105505. PubMed ID: 37805106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Absolute Quantitation of
    Wang Q; Liu Z; Liu Y; Chen H
    J Am Soc Mass Spectrom; 2022 May; 33(5):875-884. PubMed ID: 35446584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Occupational nitrosamine exposure. 1. Rubber and tyre industry.
    Spiegelhalder B; Preussmann R
    Carcinogenesis; 1983 Sep; 4(9):1147-52. PubMed ID: 6883637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analytical lifecycle management for comprehensive and universal nitrosamine analysis in various pharmaceutical formulations by supercritical fluid chromatography.
    Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
    J Pharm Biomed Anal; 2021 Apr; 197():113960. PubMed ID: 33626447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Presence of nitrosamine impurities in medicinal products.
    Sedlo I; Kolonić T; Tomić S
    Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity.
    Glowienke S; Onken U; Elhajouji A; Muthusamy S; Sangana R; Martus HJ; Bedman T; Hartmann A
    Regul Toxicol Pharmacol; 2022 Oct; 134():105245. PubMed ID: 35988810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.